Photoinitiator-free gelatin hydrogel microneedles for acute gouty arthritis treatment

Jianhua Zhang; Hengjie Zhang; Tianyou Wang; Wenjing Liu; Bao Xia; Liping Huang; Haoxing Wu; Yiwen Helen Li; Zhipeng Gu

doi:10.1126/sciadv.aei6340

Medicine & healthTreatments & drugs

Photoinitiator-free gelatin hydrogel microneedles for acute gouty arthritis treatment

Jianhua Zhang, Hengjie Zhang, Tianyou Wang, Wenjing Liu, Bao Xia, Liping Huang, Haoxing Wu, Yiwen Helen Li, Zhipeng Gu

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result

Overall, this initiator-free, photo-crosslinkable GelLA-based MNs system offered a safe, efficient, and user-friendly strategy for local drug delivery in the management of acute gouty arthritis.

Read the paper

Appeared: Friday, September 25. Science Advances. Peer-reviewed journal.

DOI: 10.1126/sciadv.aei6340

Medicine & health Treatments & drugs Sep 25, 2026
Drug repurposing identifies candidate uterus-selective tocolytics for preterm labor
This approach established a systematic strategy for identifying uterus-selective tocolytics, and these findings support further preclinical development of repurposed drugs and drug combinations for the treatment of preterm labor to improve pregnancy and neonatal outcomes.
Shajila Siricilla, Christopher J. Hansen, Jeremy Staub and 18 more — Science Translational Medicine
Peer-reviewed journalReal-world use
Medicine & health Treatments & drugs Sep 25, 2026
The nucleoside analog kamuvudine-9 shows protective and therapeutic efficacy in a mouse model of multiple sclerosis
Here, we report that in the experimental autoimmune encephalitis mouse model of MS, treatment with kamuvudine-9 (K-9), an NRTI derivative with an enhanced safety profile, prevented further neurological deficits and reversed preexisting paralysis and vision loss.
Praveen Yerramothu, Kameshwari Ambati, Joseph Magagnoli and 36 more — Science Translational Medicine
Peer-reviewed journalReal-world use
Medicine & health Treatments & drugs Sep 25, 2026
A design approach for bitopic kinase inhibitors
PonatiLink-2 outperforms clinically relevant treatments in mouse models of BCR :: ABL1 -driven cancer, both in combination with dasatinib against wild-type BCR :: ABL1 and as a single agent against ponatinib-resistant disease.
Jack W. Stevenson, Kevin Lou, Joshua A. Reynolds and 25 more — Nature
Peer-reviewed journalReal-world use
Medicine & health Treatments & drugs Sep 25, 2026
A Single Suprachoroidal Injection of AXT107 (Gersizangitide), a Multimodal, Long-Acting Integrin-Disrupting Peptide, in Patients with Neovascular Age-Related Macular Degeneration: Results of the Phase 1/2a DISCOVER Trial
Conclusions In this first-in-human study, a single suprachoroidal injection of AXT107 up to 0.5 mg was well tolerated through Week 40, with no drug-related serious adverse events, no clinically significant intraocular inflammation, and no sustained IOP elevations.
N. B. Pandey, A. C. Mirando, D. R. P. Almeida and 6 more — medRxiv
PreprintReal-world use
Medicine & health Treatments & drugs Sep 25, 2026
Etuvetidigene Autotemcel for the Treatment of Wiskott–Aldrich Syndrome
CONCLUSIONS: Our results show that the effects of etu-cel are consistent with a sustained clinical benefit in persons with Wiskott-Aldrich syndrome.
Francesca Ferrua, Sabina Cenciarelli, Stefania Giannelli and 36 more — New England Journal of Medicine
Peer-reviewed journalReal-world use

All new papers on Treatments & drugs

Photoinitiator-free gelatin hydrogel microneedles for acute gouty arthritis treatment

In the authors' words

More on Treatments & drugs that day

Drug repurposing identifies candidate uterus-selective tocolytics for preterm labor

The nucleoside analog kamuvudine-9 shows protective and therapeutic efficacy in a mouse model of multiple sclerosis

A design approach for bitopic kinase inhibitors

A Single Suprachoroidal Injection of AXT107 (Gersizangitide), a Multimodal, Long-Acting Integrin-Disrupting Peptide, in Patients with Neovascular Age-Related Macular Degeneration: Results of the Phase 1/2a DISCOVER Trial

Etuvetidigene Autotemcel for the Treatment of Wiskott–Aldrich Syndrome